BOT Botanix Pharmaceuticals Limited
Healthcare · Biotechnology
· website
$0.02
52wk 0.02 – 0.17
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A for treating atopic dermatitis. The company was incorporated in 1984 and is based in Melbourne, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$57.42M
P/E (trailing)
—
P/E (forward)
-1.83
EPS (trailing)
-0.05
Dividend yield
—
Payout ratio
0.0%
Beta
0.86
EV / EBITDA
-0.08
Price / Book
0.78
ROE
-121.1%
Operating margin
-203.7%
Net margin
0.0%
Total cash
$31.61M
Total debt
$1.08M
Current ratio
2.56
Debt / Equity
0.02
Free cash flow
$-32.33M
Avg volume
14.43M
Latest annual results
(FY ending 30 Jun 2025)
- Revenue$5.76M
- Gross profit$2.32M
- Operating income-$86.34M
- Net income-$86.40M
- Diluted EPS-0.05
- Free cash flow-$79.63M
- Net debt-$32.86M